Vilon
Also known as: Lys-Glu, Lysylglutamate, KE dipeptide
Overview
Vilon is a synthetic dipeptide (Lys-Glu) bioregulator developed by Professor Vladimir Khavinson from amino acid analysis of Thymalin, a natural thymus extract with immunomodulatory properties. It is one of the simplest bioactive peptides known, yet demonstrates measurable effects on immune cell proliferation, gene expression via chromatin remodeling, potential lifespan extension in animal models, and anti-inflammatory cytokine regulation. Its mechanism involves selective deheterochromatinization — epigenetic activation of silenced gene regions in aging cells.
Mechanism of Action
Vilon causes progressive activation (deheterochromatinization) of facultative heterochromatin in aging cells, selectively reactivating silenced genes by loosening chromatin structure without disturbing structural heterochromatin. It interacts with the CHUK gene encoding a component of the NF-κB signaling pathway, modulating cytokine production and immune cell activation at a fundamental regulatory level. Specifically, it stimulates T-cell precursor (thymocyte) proliferation and maturation, increases CD4 and CD5 expression on thymic cells, increases argyrophilic protein expression in cell nuclei, and reduces inflammatory cytokine synthesis by up to 6-fold.
Potential Benefits
- T-cell maturation and proliferation support
- CD4+ and CD5+ expression enhancement
- Up to 6-fold reduction in inflammatory cytokine synthesis
- Epigenetic activation of silenced gene regions in aging cells
- Thymic recovery after gamma radiation in animal models
- NF-κB pathway modulation balancing immune activation and inflammation
- Potential type 1 diabetes autoimmune modulation
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 100 mcg daily for 10 days |
| Intermediate | 150 mcg daily for 15 days |
| Advanced | 200 mcg daily for 20 days, repeat every 6 months |
| Cycle Duration | 10-20 days |
Khavinson dipeptide (Lys-Glu). Immune system bioregulator.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Standard Russian bioregulator route.
Oral (sublingual) Lower but practical
Short dipeptide retains some oral activity.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Vilon:
Immune Bioregulator Stack
Khavinson immune-longevity protocol for age-related immune decline.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 2-5 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Lys-Glu (KE)
Side Effects & Safety
- Well-tolerated in available studies
- Minimal adverse effects reported
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Vilon for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.